Use of Nonsteroidal Antiinflammatory Drugs
An Update for Clinicians
A Scientific Statement From the American Heart Association

Elliott M. Antman, MD, FAHA; Joel S. Bennett, MD; Alan Daugherty, PhD, FAHA; Curt Furberg, MD, PhD, FAHA; Harold Roberts, MD, FAHA; Kathryn A. Taubert, PhD, FAHA

Clinical trial data have prompted questions about the degree to which patients and their physicians should consider an increased risk of cardiovascular or cerebrovascular events when selecting medications for pain relief. Since the 2005 publication of a Science Advisory on the use of nonsteroidal antiinflammatory drugs (NSAIDs) by the American Heart Association, several important events have occurred that have served as the catalyst for this update for clinicians. (1) Additional data from randomized controlled trials of cyclooxygenase (COX)-2–selective agents have been reported and summarized in meta-analyses, which has reinforced the concern about cardiovascular events with COX-2 inhibitors (coxibs; Figure 1). (2) Several reports have appeared that have identified an increased risk of cardiovascular events even with the nonselective NSAIDs, which has raised concern about the use of those agents as well (Table). (3) Regulatory authorities in several regions of the world have introduced warning statements and advisories to both healthcare professionals and the lay public about the use of various NSAIDs (Figures 2 and 3).

In September 2004, Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) because of an increased risk of heart attack and stroke. In early December 2004, the US Food and Drug Administration (FDA) announced a “black box” warning for valdecoxib (Bextra), stating that its use in patients undergoing coronary artery bypass graft surgery is contraindicated. A week later, the National Institutes of Health (NIH) suspended the use of celecoxib (Celebrex) in the Adenoma Prevention with Celecoxib (APC) clinical trial in the Adenoma Prevention with Celecoxib (APC) clinical trial because of increased cardiovascular events. The drug was not removed from the market, but the FDA advised physicians to consider alternative therapy or to use the smallest effective dose of Celebrex. Three days later, the NIH announced that the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) showed an increase in the risk of cardiovascular events in patients given naproxen but not in those given celecoxib; the trial was halted. At the end of 2004, the FDA issued a public health advisory summarizing the agency’s recent recommendations for the use of the NSAID products Vioxx, Bextra, Celebrex, and naproxen. To quote from the public health advisory:

- “Physicians prescribing Celebrex (celexcoxib) or Bextra (valdecoxib) should consider this emerging information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal (GI) bleeding, have a history of intolerance to nonselective NSAIDs, or are not doing well on nonselective NSAIDs may be appropriate candidates for Cox-2 selective agents.”
- “Individual patient risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account for each prescribing situation.”
- “Consumers are advised that all over-the-counter (OTC) pain medications, including NSAIDs, should be used in strict accordance with the label directions. If use of an (OTC) NSAID is needed for longer than ten days, a physician should be consulted.”

At a joint meeting, 2 FDA Advisory Committees and 12 ad hoc members discussed the overall benefit-to-risk considerations for selective COX-2 NSAIDs and related agents in mid-February 2005. The 32-person panel was unanimous in its conclusion that celecoxib significantly increases the risk of cardiovascular events in a dose-dependent manner. The committee recommended, however, that celecoxib be allowed to remain on the US market under several conditions, such as the addition of a “black box” warning to the labeling, restrictions on direct-to-consumer advertising, and the development of a patient medication guide. Assumptions included...
that if celecoxib were to be used, it should be in patients who have not achieved pain control with nonselective NSAIDs, it should be used in the lowest possible dose for the shortest time necessary, and high-risk cardiac patients should be fully informed about the excess cardiovascular risks. Unanimous votes also supported the conclusions that the other 2 FDA-approved selective COX-2 inhibitors, valdecoxib and rofecoxib, increase the risk of cardiovascular events, which signaled a class effect of the selective COX-2 inhibitors. At the hearing, in a split vote, it was recommended that valdecoxib remain on the market; rofecoxib had already been withdrawn from the US market by the manufacturer. Finally, the panel voted unanimously that the labeling for the nonselective NSAIDs include information on the absence of long-term clinical trial data to assess the potential cardiovascular effects of these drugs. It also recommended that future active-control trials include naproxen as the primary comparator. Caution was advised to prevent warnings on over-the-

![Figure 1. Comparison of effects of different selective COX-2 inhibitors vs placebo on myocardial infarction. Event numbers and person-years of exposure, with corresponding mean annual event rates in parentheses, are presented for patients allocated to selective COX-2 inhibitor or placebo. Event rate ratios for pooled data with 95% CIs are indicated by a diamond; rate ratios for individual selective COX-2 inhibitors, with 99% CIs, are indicated by a square and horizontal line. Diamonds to the right of the solid line indicate hazard with a selective COX-2 inhibitor compared with placebo. As noted, there was a significant increase in the rate ratio for myocardial infarction with COX-2 inhibitors compared with placebo. Similar analyses (data not shown) include rate ratios of 1.42 (1.13 to 1.78; \( P=0.003 \)) for vascular events, 1.02 (0.71 to 1.47; \( P=0.9 \)) for stroke, and 1.49 (0.97 to 2.29; \( P=0.07 \)) for vascular death with COX-2 inhibitors compared with placebo. Modified and reproduced from Kearney et al,\(^2\) with permission from the BMJ Publishing Group.](image-url)

### TABLE. Nonselective NSAIDs and CV Risk

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Outcome</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Versus placebo or no treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-analysis of RCTs(^2)</td>
<td>Vascular events</td>
<td>0.92</td>
<td>0.67–1.26</td>
</tr>
<tr>
<td>Meta-analysis of OSs(^3)</td>
<td>CV events, mostly MI</td>
<td>0.97</td>
<td>0.87–1.07</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-analysis of RCTs(^2)</td>
<td>Vascular events</td>
<td>1.51</td>
<td>0.96–2.37</td>
</tr>
<tr>
<td>Meta-analysis of OSs(^3)</td>
<td>CV events, mostly MI</td>
<td>1.07</td>
<td>0.97–1.18</td>
</tr>
<tr>
<td>Registry(^4)</td>
<td>Recurrent MI</td>
<td>1.25</td>
<td>1.07–1.46</td>
</tr>
<tr>
<td>Registry(^4)</td>
<td>Mortality</td>
<td>1.50</td>
<td>1.36–1.67</td>
</tr>
<tr>
<td>Diclofenac</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-analysis of RCTs(^2)</td>
<td>Vascular events</td>
<td>1.63</td>
<td>1.12–2.37</td>
</tr>
<tr>
<td>Meta-analysis of OSs(^3)</td>
<td>CV events, mostly MI</td>
<td>1.40</td>
<td>1.16–1.70</td>
</tr>
<tr>
<td>Registry(^4)</td>
<td>Recurrent MI</td>
<td>1.54</td>
<td>1.23–1.93</td>
</tr>
<tr>
<td>Registry(^4)</td>
<td>Mortality</td>
<td>2.40</td>
<td>2.09–2.80</td>
</tr>
<tr>
<td><strong>Versus selective COX-2 inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-analysis of RCTs(^2)</td>
<td>Vascular events</td>
<td>0.64</td>
<td>0.49–0.83</td>
</tr>
<tr>
<td>Any non-naproxen NSAID (primarily diclofenac or ibuprofen)</td>
<td>Vascular events</td>
<td>1.14</td>
<td>0.89–1.45</td>
</tr>
<tr>
<td>Meta-analysis of RCTs(^2)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RCTs indicates randomized, controlled trials; OSs, observational studies; CV, cardiovascular; and MI, myocardial infarction.
dose for the shortest time necessary to control symptoms. It is heart disease, and that all patients take the lowest effective that they be avoided in patients with risk factors for coronary contraindications that selective COX-2 inhibitors be considered contrain- absolute, and no mention of the recommendation for low tions by the advisory panel. The black box warning states that counter products about the risks of long-term use from increasing statement now appears in the package insert for agents in the “traditional” NSAID group, emphasizing the increased risk of cardiovascular events with their use. This example is from the package insert (January 2006) of diclofenac, a commonly prescribed NSAID. Similar black box warnings appear in the package inserts for other NSAIDs (see Figure 4).

FDA decisions only partially followed the recommendations by the advisory panel. The black box warning states that celecoxib may cause increased risk (Figure 3). There is no comment on the magnitude of the increase in risk, relative or absolute, and no mention of the recommendation for low doses and short durations of treatment. The box contains the general statement that “all NSAIDs may have a similar risk” but includes no recognition of known differences among the nonselective NSAIDs (Figure 2).

The European Medicine Agency issued the recommendations that selective COX-2 inhibitors be considered contrain- indicated in patients with ischemic heart disease and/or stroke, that they be avoided in patients with risk factors for coronary heart disease, and that all patients take the lowest effective dose for the shortest time necessary to control symptoms. It is unclear whether the findings for selective COX-2 inhibitors are also relevant for nonselective NSAIDs.

### Background Scientific Information on COX Inhibitors

The primary property of this class of drugs is the inhibition of COX. There are 2 major COX isoenzymes: COX-1 is expressed constitutively (constantly) in most tissues, whereas COX-2 is induced in inflammation. Both COX-1 and COX-2 use arachidonic acid to generate the same product, prostaglandin H\(_2\). A number of enzymes further modify this product to generate bioactive lipids (prostanoids) such as prostacyclin, thromboxane A\(_2\), and prostaglandins D\(_2\), E\(_2\), and F\(_2\). These prostanoids influence immune, cardiovascular, gastro- intestinal (GI), renovascular, pulmonary, central nervous system, and reproductive function. Of note, it is now recognized that COX-2 is expressed in normal endothelial cells in response to shear stress and that inhibition of COX-2 is associated with suppression of prostacyclin synthesis. On the basis of experiments in animals and observations from clinical trials and registries, it has been proposed that major cardiovascular consequences of COX-2 inhibition include a shift in the prothrombotic/antithrombotic balance on endothelial surfaces toward thrombosis; an increase in sodium and water retention, leading to edema, as well as exacerbations of heart failure and hypertension; and loss of the protective effects of COX-2 upregulation in the setting of myocardial ischemia and infarction, which leads to a larger infarct size, greater thinning of the left ventricular wall in the infarct zone, and an increased tendency to myocardial rupture.

A variety of NSAIDs can block the enzymatic activity of COX; they vary in their chemical structure and relative ability to block the COX-1 versus the COX-2 isoenzymes (Figure 4). The COX-2 inhibitors also vary in their selectivity for the COX-2 versus the COX-1 enzyme (for medications currently or formerly on the market in the United States, rofecoxib > valdecoxib > parecoxib > celecoxib). Other COX-2 inhibitors are under development and may be introduced into the US market in the future. The differences in the biological effects of COX inhibitors are a consequence of the degree of selectivity for COX-2 versus COX-1 and tissue-specific variations in the distribution of COX and related proteins.
enzymes that convert prostaglandin H₂ into specific prostanoids.

For example, several prostanoids, including prostaglandin E₂ and prostacyclin, are both hyperalgesic (elicit an increased sense of pain) and gastroprotective. Thus, nonselective COX inhibition with agents such as aspirin, ibuprofen, indomethacin, and naproxen, which inhibit both COX-1 and COX-2 enzymes, provides effective pain relief for inflammatory conditions but carries with it a risk for erosive gastritis and GI bleeding. Selective COX-2 inhibitors (valdecoxib, rofecoxib, celecoxib, and others yet in development) were developed to minimize GI toxicity because of the relative paucity of COX-2 expression in the GI tract and the relative abundance of COX-2 expression in inflamed and painful tissues.

In the cardiovascular system, the products of COX regulate complex interactions between platelets and the vessel wall. Prostacyclin is the dominant prostanoid produced by endothelial cells. In addition to producing local muscle cell relaxation and vasodilation, prostacyclin can interact with platelet IP receptors, thereby antagonizing aggregation. Platelets contain only COX-1, which converts arachidonic acid to the potent proaggregatory, vasoconstrictive eicosanoid thromboxane A₂ (TXA₂), the major COX product formed by platelets. Nonselective COX inhibition with aspirin is effective for arterial thrombosis because of its ability to reduce COX-1–dependent production of platelet TXA₂; however, selective inhibition of COX-2 could produce a relative reduction in endothelial production of prostacyclin, while leaving the platelet production of TXA₂ intact. It has been speculated that this imbalance of hemostatic prostanoids might increase the risk for thrombotic cardiovascular events. COX-2 inhibitors, like NSAIDs, also raise blood pressure and increase the incidence of heart failure significantly compared with placebo. By elevating blood pressure, NSAIDs, particularly coxibs, attenuate the benefit of previously prescribed antihypertensive therapy and may also move certain patients not previously diagnosed as hypertensive over the threshold for initiation of treatment for hypertension.

It has been postulated that the differences in relative selectivity for COX inhibition affect the likelihood of a patient experiencing adverse cardiovascular or GI complications as a consequence of using NSAIDs (Figure 6). An example of the importance of understanding the relative selectivity for COX inhibition is found in the interpretation of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program. This program (consisting of the Etoricoxib versus Diclofenac sodium Gastrointestinal tolerability and Effectiveness [EDGE], EDGE II, and MEDAL trials) evaluated the highly COX-2–selective agent etoricoxib (not marketed in the United States) versus diclofenac, a commonly prescribed NSAID that is relatively more selective for COX-2 inhibition than for COX-1 inhibition and has a black box warning in the package insert. The MEDAL program randomized 34,701 patients with either rheumatoid arthritis or osteoarthritis to either etoricoxib or diclofenac and reported noninferiority of etoricoxib compared with diclofenac with regard to cardiovascular thrombotic (arterial and venous) events (hazard ratio 0.95, 95% confidence interval [CI] 0.81 to 1.11) in a prespecified per-protocol analysis. According to an intention-to-treat analysis through the end of follow-up, the hazard ratio for the primary composite end point of vascular death, myocardial infarction, or stroke through the end of follow-up was 1.02 (95% CI 0.87 to 1.18). Although the results of the MEDAL
MEDAL program also reported higher rates of discontinuation for edema and hypertension with etoricoxib, two complications that may represent important limitations to its use.23,29,32

Prostacyclin may also retard the pathogenesis of atherosclerosis,19 and inhibition of prostacyclin with a COX-2 inhibitor has been predicted to promote lesion formation19; however, results in different mouse models of atherosclerosis have been contradictory.33–39

**Recommendations for Management**

From both the patient’s and the physician’s perspectives, the problem lies in balancing the risks and benefits of medica-

![Figure 6](http://circ.ahajournals.org/)
tions for pain relief.\(^3\) Of course, this is not unique to these medications, but their use highlights the issues to be considered. Below are several questions that should be considered when one makes treatment decisions about pain medications in patients with or at high risk for cardiovascular disease. A suggested stepped-care approach to management of patients with musculoskeletal symptoms is shown in Figure 7 and discussed in detail below.

First, What Are the Treatment Considerations?

Musculoskeletal symptoms should be categorized as those that result from tendonitis/bursitis, those that result from degenerative joint problems (eg, osteoarthritis), or those that result from inflammatory joint problems (eg, rheumatoid arthritis). \(^4\) Initial treatment should focus on nonpharmacological approaches (eg, physical therapy, heat/cold, orthotics). \(^4\)

For patients whose symptoms are not controlled by nonpharmacological approaches, pharmacological treatments should then be considered. When choosing any medication, both safety and efficacy should be considered. In general, the least risky medication should be tried first, with escalation only if the first medication is ineffective. In practice, this usually means starting with acetaminophen or aspirin at the lowest efficacious dose, especially for short-term needs. Despite the potential for abuse, a role remains for narcotic medications for short-term pain relief. It should be recognized that with the exception of aspirin, the “low-risk” medications mentioned above have not been subjected to randomized clinical trials to conclusively demonstrate their superior safety.

In patients who do not tolerate these simple interventions or who require long-term or high-dose therapy, the issues become more complex. Long-term or high-dose therapy with aspirin and other NSAIDs is associated with increased risk for GI bleeding. Occasionally, high-dose acetaminophen can result in hepatic toxicity, especially in patients who consume excess alcohol. When acetaminophen, aspirin, and perhaps even narcotic medications (for acute pain) are not effective, tolerated, or appropriate, it may be reasonable to consider an NSAID as the next step; however, this should be coupled with the realization that effective pain relief may come at the cost of a small but real increase in risk for cardiovascular or cerebrovascular complications (moving below the horizontal line in Figure 7).

The scientific evidence to date (Table) indicates that important differences exist between these agents in terms of risk of major thrombotic events. Clinicians are cautioned against relying on meta-analyses that involve an incomplete set of trials, contain small numbers of events, and focus only on short-term follow-up when assessing the relative risks of various agents. \(^2\) Naproxen appears to be the preferred choice. Although the ADAPT study, which investigated prevention of development of Alzheimer’s disease with either naproxen or celecoxib compared with placebo, raised concerns about the safety of naproxen, the trial had major limitations. \(^3\) These include a very high rate of patients lost to follow-up (almost 10%), a large number of enrollees who did not receive their study medication, a lack of specified criteria for the cardiovascular events, and no central adjudication of the reported nonfatal events. The small number of reported cardiovascular deaths, myocardial infarctions, and strokes in the naproxen and placebo groups in ADAPT do not materially alter the relative risk and 95% CI for naproxen shown in the Table. As noted in Figure 7, if symptoms are not adequately controlled by a nonselective NSAID, subsequent steps involve prescription of drugs with increasing degrees of COX-2–inhibitory activity, ultimately concluding with the COX-2–selective NSAIDs.

Second, What Patient Characteristics Should Be Considered?

Patients with a history of or risk for GI bleeding, especially in relation to aspirin or other nonselective NSAID use, might be given acetaminophen initially. Alternatively, proton-pump inhibitors may diminish the risk of recurrent GI bleeding in subjects who require low-dose aspirin. \(^4\) If these alterna-
tives are not possible, it may be reasonable to consider a COX-2 inhibitor if the potential benefits of treatment are believed to outweigh the potential cardiovascular risks. Patients who are tolerant of nonspecific NSAIDs but find them insufficient could also consider a COX-2 inhibitor.

Patients with or at risk for active atherosclerotic processes, including those with recent bypass surgery, unstable angina or myocardial infarction, or ischemic cerebrovascular events, have greater increases in absolute risk for adverse cardiovascular effects when given a COX inhibitor. (It is difficult to provide precise estimates of the absolute increase in risk because the excess number of events is related to such factors as the underlying risk of the patient, the relative risk of the drug, and the duration of follow-up.) The authors of one large report estimated that in patients with a prior myocardial infarction, the excess risk of mortality is \( \approx 6 \) deaths per 100 person-years of treatment with a COX-2 inhibitor compared with no NSAID treatment.4 In these patients, prudence dictates extra caution in the use of COX-2 inhibitors, which should include the use of only the recommended doses and for the shortest period of time required to control symptoms. Every effort should be made to assess and treat modifiable risk factors before and during NSAID treatment. COX inhibitors can lead to impaired renal perfusion, sodium retention, and increases in blood pressure, which may contribute to their adverse cardiovascular effects.22 Renal function and blood pressure should be monitored in subjects taking COX-2 inhibitors. This is especially true when these drugs are given to subjects with preexisting hypertension, renal disease, and heart failure (Figure 7).

Third, if You Use a COX-2 Inhibitor, Does Selectivity Matter?
The available data have implicated several COX-2 inhibitors with varying degrees of selectivity. As suggested by the data summarized in the Table, Figure 1, and Figure 6, even a relative lack of COX-2 selectivity does not completely eliminate the risk of cardiovascular events, and in that regard, all drugs in the NSAID spectrum should only be prescribed after thorough consideration of the risk/benefit balance. Additional data bearing on this issue will be provided in the ongoing PRECISION trial (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen Or Naproxen; http://www.clinicaltrials.gov, No. NCT00346216), which is randomizing patients with rheumatoid arthritis or osteoarthritis to celecoxib, ibuprofen, or naproxen, the latter being 2 NSAIDs that are further toward the non–COX-2 end of the spectrum (Figure 6).

Fourth, Can Patients Using Aspirin for Cardioprotection Also Use NSAIDs or Selective COX-2 Inhibitors for Pain Relief?
Evidence indicates that ibuprofen, but not rofecoxib (a COX-2 inhibitor), acetaminophen, or diclofenac, interferes with aspirin’s ability to irreversibly acetylate the platelet COX-1 enzyme, and it would be expected, although it has not been proved, that this would reduce the protective effect of aspirin on risk for atherothrombotic events. Per an FDA advisory:

- Patients taking immediate release low-dose aspirin (not enteric coated) and ibuprofen 400 mg should take the ibuprofen at least 30 minutes after aspirin ingestion, or at least 8 hours before aspirin ingestion to avoid any potential interaction.
- Recommendations about concomitant use of ibuprofen and enteric-coated low dose aspirin cannot be made based on available data. One study showed that the antiplatelet effect of enteric-coated low dose aspirin is attenuated when ibuprofen 400 mg is dosed 2, 7, and 12 hours after aspirin.

Of note, the combination of aspirin (necessary for protection against cardiovascular events) and a coxib may ameliorate the gastric mucosal protective effect of COX-2 inhibition. The combination of the two may also prolong the time for recovery from gastric mucosal injury.

Summary
Current evidence indicates that selective COX-2 inhibitors have important adverse cardiovascular effects that include increased risk for myocardial infarction, stroke, heart failure, and hypertension. The risk for these adverse effects is likely greatest in patients with a prior history of or at high risk for cardiovascular disease. In these patients, use of COX-2 inhibitors for pain relief should be limited to patients for whom there are no appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary. More long-term data are needed to fully evaluate the extent to which these important adverse cardiovascular effects may be offset by other beneficial effects of these medications. More data are also needed on the cardiovascular safety of conventional NSAIDs. Until such data are available, the use of any COX inhibitor, including over-the-counter NSAIDs, for long periods of time should only be considered in consultation with a physician.

The debate about the increased risk of cardiovascular events attributed to the selective COX-2 inhibitors and the nonselective NSAIDs is part of a broader national debate about drug safety. Optimal safety evaluation of drugs requires timely and complete submission of scientific data from the manufacturers, as well as increased funding and authority granted to the FDA by Congress.

Acknowledgments
The authors thank Matthew Liang, MD, Department of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, Mass, for his helpful comments on this paper.
Disclosures

Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers' Bureau/ Honoraria</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elliott M. Antman</td>
<td>Brigham and Women's Hospital, Harvard Medical School</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joel S. Bennett</td>
<td>University of Pennsylvania</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alan Daugherty</td>
<td>University of Kentucky</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Curt Furberg</td>
<td>Wake Forest University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harold Roberts</td>
<td>University of North Carolina</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kathryn A. Taubert</td>
<td>American Heart Association</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit.

References


27. Cannon CP, Curtis SP, Bolognese JA, Laine L; MEDAL Steering Committee. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program;


32. Zarraga IG, Schwarz ER. Coxibs and heart disease: what we have learned and what else we need to know. *J Am Coll Cardiol.* 2007;49:1–14.


Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association
Elliott M. Antman, Joel S. Bennett, Alan Daugherty, Curt Furberg, Harold Roberts and Kathryn A. Taubert

Circulation. 2007;115:1634-1642; originally published online February 26, 2007;
doi: 10.1161/CIRCULATIONAHA.106.181424
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/115/12/1634

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/